Actinium Pharmaceuticals (ATNM) Profit After Tax (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Profit After Tax of -$5.5 million for Q1 2026, up 65.35% year-over-year from -$3.3 million in Q1 2025, and up 7.04% quarter-over-quarter from -$5.9 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Profit After Tax (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Profit After Tax for 17 consecutive years, with -$5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 65.35% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$23.5 million (up 48.43% YoY), while the FY2025 annual figure was -$33.9 million, up 11.39% from the prior year.
- Profit After Tax rose to -$5.5 million in Q1 2026 per ATNM's latest filing, from -$5.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$5.1 million in Q1 2022 and bottomed at -$15.9 million in Q1 2025.
- Historically, Profit After Tax has averaged -$9.4 million across 5 years, with a median of -$9.3 million in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax plunged 115.19% — and 2026, when it surged 65.35%.
- Actinium Pharmaceuticals' Profit After Tax stood at -$10.6 million in 2022, then increased by 12.43% to -$9.3 million in 2023, then gained by 28.66% to -$6.7 million in 2024, then climbed by 10.7% to -$5.9 million in 2025, then grew by 7.04% to -$5.5 million in 2026.
- Business Quant data shows ATNM's Profit After Tax at -$5.5 million in Q1 2026, -$5.9 million in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.90 Mn |
| Mar 31, 2026 | -5.52 Mn |
| Dec 31, 2025 | -5.94 Mn |
| Sep 30, 2025 | -5.13 Mn |
| Jun 30, 2025 | -6.88 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -6.65 Mn |
| Sep 30, 2024 | -11.57 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -8.67 Mn |
| Dec 31, 2023 | -9.32 Mn |
| Sep 30, 2023 | -13.28 Mn |
| Jun 30, 2023 | -15.18 Mn |
| Mar 31, 2023 | -11.04 Mn |
| Dec 31, 2022 | -10.65 Mn |
| Sep 30, 2022 | -9.47 Mn |
| Jun 30, 2022 | -7.77 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -8.01 Mn |
| Sep 30, 2021 | -6.42 Mn |